From Drug Benefit News - In the face of cost increases from an emerging category of cholesterol-lowering drugs known as PCSK9 inhibitors, new research posted last week by two different PBMs suggests that plans have work left to do when it comes to encouraging the use of low-cost statins and rechallenging patients at lower doses before they are declared statin intolerant and potentially moved to the higher cost PCSK9s. Read more
From Drug Benefit News - Walgreens Boots Alliance, Inc. (WBA) on Oct. 28 unveiled plans to purchase Rite Aid Corp. for $9 a share, or a total enterprise value of approximately $17.2 billion after factoring in debt, creating what many are calling a retail “behemoth” in the pharmacy space. Given that WBA Executive Vice Chairman and CEO Stefano Pessina this year hinted several times at possible merger and acquisition activity, the proposed deal came as… Read more
From Drug Benefit News - A recent analysis of post-marketing data by Advera Health Analytics, Inc. suggested that AbbVie Inc.’s Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets) is the least safe option of three leading hepatitis C treatments and may be associated with at least $6.5 million in avoidable downstream medical expenses. Read more
Check out all of the benefits, sample issues & more!